Prednisone Dosing for Recurrent PMR Flare
For this 75-year-old man with a recurrent PMR flare, increase prednisone to the dose that was effective before the relapse occurred (the pre-relapse dose), then taper gradually back down to the dose at which the relapse occurred over 4-8 weeks. 1
Management Algorithm for PMR Relapse
Step 1: Determine the Pre-Relapse Dose
- Identify what prednisone dose the patient was taking when symptoms were last controlled
- This becomes your target dose for relapse therapy
Step 2: Increase to Pre-Relapse Dose
- Immediately increase oral prednisone to the previously effective (pre-relapse) dose 1
- This is the cornerstone recommendation from the 2015 EULAR/ACR guidelines
- Do not exceed 25 mg/day unless the patient had initially required higher doses 1
Step 3: Tapering After Relapse Control
Once symptoms resolve and inflammatory markers normalize:
- Decrease gradually within 4-8 weeks to the dose at which the relapse occurred 1
- Then resume the standard slow taper of 1 mg every 4 weeks 1
- The elevated CRP (3.86 mg/dL, normal <0.5 mg/dL) confirms active inflammation requiring treatment
Important Clinical Considerations
Risk Factors in This Patient
At age 75, assess for:
- Glucocorticoid-related adverse event risks: diabetes, osteoporosis, hypertension, cardiovascular disease, glaucoma 1
- Relapse risk factors: The elevated CRP suggests active disease requiring adequate dosing 1
Common Pitfall to Avoid
Do not use insufficient doses for relapse therapy. The most common error is under-dosing during a flare, which leads to prolonged symptoms and ultimately higher cumulative steroid exposure 1. The guideline strongly recommends returning to the pre-relapse dose rather than making small incremental increases.
Consider Methotrexate Addition
Given this is a recurrent flare, consider adding methotrexate 7.5-10 mg/week as a steroid-sparing agent, particularly if:
- Multiple relapses have occurred
- The patient has significant comorbidities increasing glucocorticoid risk
- Prolonged therapy is anticipated 1
Monitoring Strategy
- Follow-up in 2-4 weeks to assess response 1
- Expect clinical improvement within 2 weeks and near-complete response by 4 weeks 1
- Monitor CRP to confirm normalization (ideally ≤0.17 mg/dL within 1 month predicts better outcomes) 2
- Schedule visits every 4-8 weeks during active tapering 1
Alternative Consideration
If the patient has multiple comorbidities or has experienced significant steroid-related adverse events, intramuscular methylprednisolone (120 mg every 3 weeks) may be considered as an alternative, though this is typically reserved for initial therapy rather than relapse management 1.